Fenofibrate Capsules Generic Name & Formulations
Fenofibrate 67mg, 134mg, 200mg; caps (micronized).
Fenofibrate Capsules Indications
Adjunct to diet: in severe hypertriglyceridemia; and to reduce elevated total-C, LDL-C, ApoB, and TG, and to increase HDL-C in primary hyperlipidemia and mixed dyslipidemia.
Fenofibrate Capsules Dosage and Administration
Take with food. Hypertriglyceridemia: 67–200mg/day; adjust in 4–8 week intervals; max 200mg/day. Hypercholesterolemia, dyslipidemia: 200mg/day. Renal impairment (CrCl<50mL/min): initially 67mg/day. Discontinue if inadequate response after 2 months on max dose.
Fenofibrate Capsules Contraindications
Severe renal impairment. Dialysis. Active liver disease. Primary biliary cirrhosis. Unexplained persistent liver dysfunction. Gallbladder disease. Nursing mothers.
Fenofibrate Capsules Boxed Warnings
Fenofibrate Capsules Warnings/Precautions
Renal impairment. Monitor CBCs for first year; monitor liver function, discontinue if ALT (SGPT) levels >3xULN persist. Discontinue if markedly elevated CPK levels, myopathy, or gallstones occur. Pregnancy.
Fenofibrate Capsules Pharmacokinetics
Fenofibrate Capsules Interactions
Avoid statins. Potentiates oral anticoagulants (monitor). Allow at least 1 hour before or 4–6 hours after bile acid sequestrants. Caution with immunosuppressants (eg, cyclosporine), other nephrotoxic drugs.
Fenofibrate Capsules Adverse Reactions
Abnormal liver function tests, elevated CPK, respiratory or GI effects, myopathy, cholelithiasis, pancreatitis, increased creatinine, rash; rare: rhabdomyolysis, transient hematologic changes, blood dyscrasias.
Fenofibrate Capsules Clinical Trials
Fenofibrate Capsules Note
Formerly known under the brand name Lofibra.
Fenofibrate Capsules Patient Counseling